Related Experiment Video
Updated: May 6, 2026
06:57
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
Published on: February 20, 2020
7.7K
Therapeutic options for visceral leishmaniasis.
Begoña Monge-Maillo1, Rogelio López-Vélez
1Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Ramón y Cajal Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Carretera de Colmenar Km 9,1, 28034, Madrid, Spain.
Drugs
|October 31, 2013
Summary
Visceral leishmaniasis (VL), or Kala-Azar, treatment varies by location and drug resistance. This review offers evidence-based therapeutic recommendations for this serious protozoal infection.
Area of Science:
- Infectious Diseases
- Parasitology
- Tropical Medicine
Background:
- Visceral leishmaniasis (VL), also known as Kala-Azar, is a severe protozoal disease.
- Caused by Leishmania donovani and Leishmania infantum, VL affects multiple organs.
- Treatment decisions are complex, influenced by geography, drug resistance, and patient health.
Purpose of the Study:
- To conduct an exhaustive literature review on visceral leishmaniasis treatment.
- To provide evidence-based therapeutic recommendations for VL.
- To stratify recommendations by Leishmania species and geographic region.
Main Methods:
- Systematic literature search for studies on VL treatment.
- Analysis of treatment efficacy and safety data.
- Synthesis of findings to develop stratified recommendations.
Main Results:
- Identified diverse therapeutic options for VL.
- Highlighted the impact of geographical location and Leishmania species on treatment effectiveness.
- Noted the influence of drug resistance and co-infections on therapeutic choices.
Conclusions:
- Therapeutic strategies for VL must be tailored to specific contexts.
- Evidence-based recommendations are crucial for optimizing patient outcomes.
- Further research is needed to address emerging challenges in VL treatment.
